Unlocking the Potential of Ribosomal Protein L21 Pseudogene 134 as a Drug Target and Biomarker

Target Name: RPL21P134

NCBI ID: G728782

RPL21P134

Other Name(s): ribosomal protein L21 pseudogene 134 | RPL21_61_1788 | Ribosomal protein L21 pseudogene 134

Unlocking the Potential of Ribosomal Protein L21 Pseudogene 134 as a Drug Target and Biomarker

Ribosomal protein L21 (RPL21) is a key regulator of protein synthesis in eukaryotic cells, responsible for ensuring the accurate and efficient translation of mRNAs into functional proteins. The RPL21 gene has been well-studied, and several splice variants have been identified. However, a recent study has identified a putative pseudogene, RPL21P134, which has elicited significant interest due to its potential involvement in cellular processes. This article will explore the biology of RPL21P134, its potential drug target properties, and its potential as a biomarker for various diseases.

Biochemistry and Function

RPL21 is a 21-kDa protein that plays a crucial role in the regulation of protein synthesis, specifically in the ribosome complex. It is composed of a unique N-terminal region that contains a conserved nucleotide sequence responsible for forming a nucleotide-binding domain (NBD), as well as a C-terminal region that contains a T-loop and a hypervariable region (HVR). The NBD is essential for the protein's stability and functions as a binding site for small molecules, nucleotides, and proteins.

RPL21P134 is a specific splice variant of the RPL21 gene that has been identified by bioinformatic analysis. It is characterized by a single exon and a unique 5' end that results in a different reading frame compared to the original RPL21 gene. RPL21P134 has been shown to have distinct functional properties compared to the full-length RPL21 protein. For example, studies have shown that RPL21P134 is highly stable in the presence of bound factors, such as small nucleotides and proteins, and that it can interact with these factors to regulate protein synthesis.

Drug Target Potential

The potential drug target of RPL21P134 is its unique 5' end that gives it a distinct 5'-end signature compared to the original RPL21 gene. This 5'-end signature is conserved across different splice variants of RPL21, including RPL21P134. Therefore, researchers are interested in exploring the implications of this 5'-end signature for protein function and potential drug targets.

One potential drug target for RPL21P134 is its NBD, which is known to play a crucial role in the regulation of protein synthesis and stability. Several studies have shown that NBDs can be targeted by small molecules, such as inhibitors of the translation machinery or drugs that interfere with protein synthesis. Therefore, compounds that can inhibit the activity of RPL21P134's NBDs may be effective drugs against various diseases, including cancer, neurodegenerative diseases, and bacterial infections.

In addition to its potential as a drug target, RPL21P134 has also been identified as a potential biomarker for various diseases. The 5'-end signature of RPL21P134 makes it a stable protein that can be used as a protein biomarker in various disease states, including cancer, neurodegenerative diseases, and infectious diseases. For example, RPL21P134 has been shown to be overexpressed in various cancer tissues and has been used as a biomarker for cancer diagnosis and monitoring.

Biomarker Potential

RPL21P134 has also been identified as a potential biomarker for various neurological and psychiatric diseases. The 5'-end signature of RPL21P134 has been shown to be altered in various neurological and psychiatric disease states, including Alzheimer's disease, Parkinson's disease, and depression. Therefore, RPL21P134 has

Protein Name: Ribosomal Protein L21 Pseudogene 134

The "RPL21P134 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL21P134 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets